CNS Pharmaceuticals (NASDAQ:CNSP) Shares Up 21.6% – What’s Next?

Shares of CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) shot up 21.6% during mid-day trading on Monday . The stock traded as high as $6.25 and last traded at $6.19. 81,852 shares traded hands during trading, an increase of 103% from the average session volume of 40,329 shares. The stock had previously closed at $5.09.

Analysts Set New Price Targets

Separately, Alliance Global Partners reaffirmed a “buy” rating on shares of CNS Pharmaceuticals in a research note on Thursday, May 22nd.

CNS Pharmaceuticals Stock Up 21.6%

The stock has a market cap of $2.79 million, a PE ratio of 0.00 and a beta of 2.64. The company has a fifty day moving average price of $9.13 and a 200 day moving average price of $20.05.

CNS Pharmaceuticals (NASDAQ:CNSP) last released its quarterly earnings data on Thursday, August 14th. The company reported ($6.42) EPS for the quarter, topping the consensus estimate of ($9.60) by $3.18.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Integrated Wealth Concepts LLC purchased a new position in CNS Pharmaceuticals during the 4th quarter valued at about $30,000. Connective Capital Management LLC purchased a new position in CNS Pharmaceuticals during the 4th quarter valued at about $34,000. XTX Topco Ltd purchased a new position in CNS Pharmaceuticals during the 4th quarter valued at about $36,000. Citadel Advisors LLC purchased a new position in CNS Pharmaceuticals during the 4th quarter valued at about $39,000. Finally, Geode Capital Management LLC grew its holdings in shares of CNS Pharmaceuticals by 90.5% during the 4th quarter. Geode Capital Management LLC now owns 387,064 shares of the company’s stock worth $47,000 after acquiring an additional 183,884 shares during the period. Hedge funds and other institutional investors own 14.02% of the company’s stock.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.